Table 6. Analysis of Selective and Potent Compounds at a Final Concentration (100 μM) Cell Viability in BHK-21 and HEK-293 Normal Cells Compared to Untreated Control and Cisplatin (a Cytotoxic Agent).

samples	% cell viability ± SD(BHK-21 cells)	% cytotoxicity ± SD(BHK-21 cells)	% cell viability ± SD(HEK-293 T cells)	% cytotoxicity ± SD(HEK-293 T cells)
control	100	0	100	0
9	98 ± 0.06	1.8 ± 0.06	72 ± 0.2	27.0 ± 0.2
10	34 ± 0.1	65.70 ± 0.07	86 ± 0.3	14 ± 0.010
11	48 ± 0.06	51 ± 0.005	72 ± 0.6	27 ± 0.06
12	35 ± 0.08	64 ± 0.03	73 ± 0.1	26.6 ± 0.06
13	94 ± 0.2	05.50 ± 0.23	86 ± 0.6	14 ± 0.09
14	47 ± 0.09	52 ± 0.14	85 ± 0.10	15 ± 0.4
15	48 ± 0.04	51.2 ± 0.23	82 ± 0.6	18 ± 0.6
17	97 ± 0.05	2.16 ± 0.05	97 ± 0.3	03 ± 0.04
18	59 ± 0.03	40.7 ± 0.04	75. ± 0.5	24 ± 0.07
19	85 ± 0.2	14.7 ± 0.01	49 ± 0.6	50 ± 0.08
20	45 ± 0.09	54.6 ± 0.02	86 ± 0.07	13 ± 0.03
21	48 ± 0.1	51.5 ± 0.06	86 ± 0.6	13 ± 0.05
22	39 ± 0.08	60.0 ± 0.05	91 ± 0.6	09 ± 0.050
23	34 ± 0.1	65.0 ± 0.06	74 ± 0.4	26 ± 0.06
24	56 ± 0.2	43.8 ± 0.01	81 ± 0.1	18 ± 0.03
25	95 ± 0.05	04.3 ± 0.09	98 ± 0.6	02 ± 0.02
26	59 ± 0.01	40.70 ± 0.1	98 ± 0.4	02 ± 0.06
cisplatin	21.0 ± 0.04	78.0 ± 0.06	23 ± 0.8	77 ± 0.09